This Swiss Medtech has been co-founded by Truffle, Symetis is specialized in minimally invasive cardiac valves. It launched its first product in 2011 and developed a new self-extending nitinol (nickel-titanium alloy) stent for TAVI, Transcatheter Aortic Valve Implantation, a peripheral arterial implantation technique.
See website
Synoptical view
- Truffle investment
- € 25M
In summary
Symetis is specialized in minimally invasive cardiac valves.
This characteristic makes the technology very tolerant with regard to the positioning of the implant before its complete release. ACURATE valves are designed to treat patients with severe and symptomatic aortic valve stenosis, who are considered at high risk of surgical valve replacement. Instead of open-heart surgery, the replacement valve is delivered by a transcatheteral percutaneous administration system. The ACURATE platform is known for its ease of use when implanting valves. Pre-acquisition the company had a turnover of €60M and was number 3 after Edwards and Medtronic. The company was sold in 2017 to Boston Scientific for a total amount of $435 million
KEY STEPS
2011
Symetis receives CE certification in September.
2012
First success for men - ACURATE TF.
2014
Symetis receives CE marking approval for the ACURATE transcatheterotransfemoral aortic valve system neo™
2015
In September, Symetis launches an initial public offering.
2016
Symetis is now ranked 3rd, ahead of Boston Scientific in Germany, with an 11% market share.
2017
Symetis is sold for $435 million to Boston Scientific.
